<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033643</url>
  </required_header>
  <id_info>
    <org_study_id>3614-002</org_study_id>
    <secondary_id>MK3614-002</secondary_id>
    <secondary_id>2009_704</secondary_id>
    <nct_id>NCT01033643</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of MK3614 (3614-002)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3614</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if MK3614, given in multiple rising doses, is safe and tolerated in
      male subjects with mild to moderate hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple rising oral doses of MK3614, measured by the number of clinical and laboratory adverse experiences</measure>
    <time_frame>14 days after administration of last dose of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg MK3614 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg and 0.25 mg MK3614 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg and 0.25 mg MK3614 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg MK3614 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg, 0.25 mg and 0.75 mg MK3614 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3614</intervention_name>
    <description>0.25 mg BID every 12 hours for 10 days</description>
    <arm_group_label>Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK3614 .75 mg 1st</intervention_name>
    <description>0.50 mg in the AM, 0.25 mg in the PM 12 hours apart for 10 days</description>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK3614 titrating down dose</intervention_name>
    <description>Day 1 subjects will receive 0.50 mg three times a day every 8 hours. Days 4-13 subjects will receive 0.50 mg twice a day every 12 hours.</description>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK3614 multiple rising dose</intervention_name>
    <description>Day 1 subjects will receive 0.50 mg twice a day every 12 hours. Day 2 subjects will receive 3 doses (0.50/0.50/0.25 mg) each 8 hours apart. Days 3-4 subjects will receive 3 doses of 0.50 mgs 8 hours apart. Days 5-14 subjects will receive 0.75 mgs twice a day every 12 hours.</description>
    <arm_group_label>Panel E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo Panel A</intervention_name>
    <description>Oral Placebo BID every 12 hours for 10 days</description>
    <arm_group_label>Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo Panel B-C</intervention_name>
    <description>Oral Placebo in the AM, 0.25 mg in the PM 12 hours apart for 10 days</description>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo Panel D</intervention_name>
    <description>Day 1 subjects will receive oral placebo three times a day every 8 hours. Days 4-13 subjects will receive oral placebo twice a day every 12 hours.</description>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo Panel E</intervention_name>
    <description>Day 1 subjects will receive oral placebo twice a day every 12 hours. Day 2 subjects will receive 3 doses of oral placebo each 8 hours apart. Days 3-4 subjects will receive 3 doses of oral placebo 8 hours apart. Days 5-14 subjects will receive oral placebo twice a day every 12 hours.</description>
    <arm_group_label>Panel E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertensive male subjects

          -  an otherwise healthy subject with grade 1 or 2 arterial hypertension being treated
             with a single antihypertensive drug

          -  subject is a nonsmoker and has not used nicotine or nicotine products for at least 6
             months

          -  subject is in generally good health

        Exclusion Criteria:

          -  subject has a history of clinically significant abnormalities or diseases

          -  subject has a history of stroke, chronic seizures, or major neurological disorder

          -  subject has a functional disability that can interfere with rising from a sitting
             position to the standing position

          -  subject has any personal or family history of a bleeding or a clotting disorder

          -  subject has a history of frequent nose bleeds or has recurrent or active gingivitis

          -  subject has a history of cancer

          -  subject has a history of clinically significant cardiac disease

          -  subject is unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs or herbal remedies approximately 2 weeks prior
             to the administration of study drug

          -  subject consumes excessive amounts of alcohol

          -  subject consumes excessive amounts of caffeinated beverages per day

          -  subject has had major surgery, donated or lost 1 unit of blood or participated in
             another investigational study within 4 weeks of study

          -  subject has a history of significant multiple and/or severe allergies (including
             latex) to prescription or non-prescription drugs or food

          -  subject is currently a regular user of any illicit drugs or has a history of drug
             abuse within approximately 1 year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

